DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Dornase Alpha (Pulmozyme®)

To Patients

To Patients

Therapeutic Approach

Mucociliary Clearance

Dornase alfa (Pulmozyme®) is an inhaled medication that thins and loosens mucus in the airways of people with CF.

Status

A Phase 3 clinical trial showed improvement in lung function and reduction in pulmonary exacerbations. It was approved for use by the FDA in 1993.

In Australia, dornase alfa 2.5mg/2.5ml (inhalation solution) is approved by the TGA and listed for reimbursement on the PBS.

Sponsor

In  the US, the program was sponsored by Genentech, Inc and the Cystic Fibrosis Foundation.

 

Contact us about Dornase Alpha (Pulmozyme®) >